Advanced Filters
noise

renal-failure Clinical Trials

A listing of renal-failure medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 571 clinical trials

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).

40 - 75 years of age All Phase 2

New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients

To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.

18 - 95 years of age All Phase N/A
C Clara Walling, BA

Transforming Hemodialysis-Related Vascular Access Education

The focus of this study is on vascular access for hemodialysis. This is a randomized clinical trial testing 3 educational approaches to help patients with advanced chronic kidney disease prepare for placement of hemodialysis vascular access. Study participants will each be assigned to one of the 3 approaches: 1) "Education", …

18 years of age All Phase N/A
D Diana Jalal, MD

Patient-driven Management of BP in CKD

The proposed research will evaluate if patients managing their blood pressure medications under the guidance of a clinical pharmacist works better to lower blood pressure than patients monitoring their blood pressure at home and the standard care. 60 Veterans with chronic kidney disease (CKD) will be included in the study. …

18 years of age All Phase 3
D Dana DaCosta

Sympatholysis in Chronic Kidney Disease

The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate).

18 - 75 years of age All Phase 1
R Robert Toto, MD

L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. A potential signal driving sympathetic nerve activity (SNA) involves accumulation of the endogenous …

35 - 75 years of age All Phase 4
k kun-Ling Tsai, Ph.D.

The Effects of Eccentric Cycling Exercise Program in Chronic Kidney Disease Patients

Progress in medical technology, enhancements in environmental cleanliness, and elevated living conditions have notably prolonged the mean life expectancy, resulting in a swift increase in the aging population. The prevalence of Chronic Kidney Disease (CKD) is more pronounced among the elderly in contrast to younger demographics. With the aging of …

55 - 85 years of age All Phase N/A
Z Zhe Li

Calcium-Phosphorus Regulation Therapy on Heart Valve Disease

The goal of this clinical trial is to learn if calcium-phosphorus regulation therapy can slow the progression of heart valve calcification in patients with degenerative heart valve disease and chronic kidney disease (CKD). The main questions it aims to answer are: Does Sevelamer lower the progression of heart valve calcification …

50 years of age All Phase 4
O Odessa R Addison, PhD DPT

Exercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength

The aging Veteran population has more frequent inpatient hospitalization than non-Veterans. In addition, older Veterans have an inability to fully recover muscle mass and function after hospital-acquired weakness. The problem of hospital-acquired weakness is greatly increased in at-risk Veteran populations such as those with chronic kidney disease (CKD). The purpose …

55 years of age All Phase N/A
A Arline Mata

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.

18 - 65 years of age All Phase 1

Simplify language using AI